SSII

Record quarterly revenue driven by strong growth in SSi Mantra installations and procedures FORT LAUDERDALE, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2026. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, with the Securities and Exchange Commission on May 13, 2026. First Quarter 2026 Overview Revenue increased 116.8% to $11.1 million from $5.1 million in the first quarter of 2025. Gross margin expanded to 48.0% from 21.2% in the first quarter of 2025. Gross profit rose 390.0% to $5.3 million from $1.1 million in the first quarter of 2025. Net loss of $3.6 million, or $(0.02) per diluted share, compared to a net loss of $5.7 million, or $(0.03) per diluted share, in the first quarter of 2025. SSi Mantra surgical robotic system installations totaled 26, up 73.3% from 15 installations in the first quarter of 2025. As of March 31, 2026 Long-term debt of $0. Cash and cash equivalents totaled $16.0 million, excluding restricted cash. SSi Mantra cumulative installed base totaled 194 across eleven countries and cumulative surgeries reached 9,744, including 157 telesurgeries, 482 cardiac procedures and 161 pediatric surgeries. CEO Commentary Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “In the first quarter of 2026 we reported record quarterly revenue of $11.1 million, up 117% year over year, driven by robust growth in SSi Mantra installations and procedures. Strong adoption by hospitals and physicians reflects the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency. Among other developments in the quarter, we received regulatory approval for the SSi Mantra for multiple indications in Sri Lanka and Kenya and for telesurgery in Indonesia and the Philippines. We also successfully completed a private placement in March 2026 that provided SS Innovations with approximately $18.6 million in gross proceeds to fuel growth initiatives.” Dr. Srivastava continued, “Looking ahead, we ai...

Strong growth in SSi Mantra installations, procedures and revenues FORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and twelve months ended December 31, 2025. The Company also filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the Securities and Exchange Commission on March 10, 2026. Fourth Quarter 2025 Overview Revenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024. Gross margin of 43.9% compared to 48.9% in the fourth quarter of 2024. Gross profit rose 60.7% to $6.4 million from $4.0 million in the fourth quarter of 2024. Net loss of $2.5 million, or $(0.01) per diluted share, compared to a net loss of $1.9 million, or $(0.01) per diluted share, in the fourth quarter of 2024. SSi Mantra surgical robotic system installations totaled 40, up 81.8% from 22 installations in the fourth quarter of 2024 and up 48.1% from 27 installations in the third quarter of 2025. Full Year 2025 Overview Revenue increased 105.7% to $42.5 million from $20.6 million in 2024. Gross margin expanded to 46.0% from 40.9% in 2024. Gross profit rose 131.2% to $19.5 million from $8.5 million in 2024. Net loss of $12.1 million, or $(0.06) per diluted share, compared to net loss of $19.2 million, or $(0.11) per diluted share, in 2024. SSi Mantra surgical robotic system installations totaled 103, up 119.1% from 47 installations in 2024. As of December 31, 2025 Long-term debt of $0. Cash and cash equivalents totaled $3.2 million, excluding restricted cash. SSi Mantra cumulative installed base totaled 168 across ten countries and cumulative surgeries reached 7,885, including 120 telesurgeries, 390 cardiac procedures and 121 pediatric surgeries. CEO Commentary Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “In the fourth quarter of 2025, we achieved strong growth in SSi Mantra installations, procedures and revenues, capping off a successful year for SS Innovations. Among our accomplishments in 2025, we gained significant share of the surgical robotics market in India, expanded into new...

Anticipated strong revenue growth driven by higher unit sales of SSi Mantra surgical robotic system FORT LAUDERDALE, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced preliminary unaudited revenue and other select operating metrics for the three and twelve months ended December 31, 2025. For the fourth quarter of 2025, the Company expects to report: Revenue of approximately $15.0 million, up 85% from revenue of $8.1 million in the fourth quarter of 2024. SSi Mantra installations of 37, up 68% from 22 installations in the fourth quarter of 2024. For the full year 2025, the Company expects to report: Revenue of approximately $43.0 million, up 108% from revenue of $20.6 million in 2024. SSi Mantra installations of 103, up 119% from 47 installations in 2024. The SSi Mantra cumulative installed base totaled 168 as of December 31, 2025, up 158% from 65 as of December 31, 2024. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We expect to report strong fourth quarter revenue growth, driven by higher unit sales of our advanced, cost-effective SSi Mantra surgical robotic system in India and abroad. We are committed to democratizing excellence in surgical care on a global scale, including in the United States and Europe. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra in the first half of 2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain in the first half of 2026. We look forward to providing additional financial details when we release our fourth quarter financial results in the latter part of February.” The Company expects to report its fourth quarter and full year 2025 financial results before the end of February. The estimated financial and operating results in this press release are preliminary, unaudited and subject to completion, and may change as a result of management's continued review. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. A...

Quarterly Revenue Increased 192.5% Year over Year to $12.8 Million Driven by Higher SSi Mantra 3 Unit Sales FORT LAUDERDALE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and nine months ended September 30, 2025. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, with the Securities and Exchange Commission on October 28, 2025. Third Quarter 2025 Overview Revenue increased 192.5% to $12.8 million from $4.4 million in the third quarter of 2024. Gross margin of 48.1% compared to 52.8% in the third quarter of 2024. Gross profit rose 166.0% to $6.2 million from $2.3 million in the third quarter of 2024. Net loss of $3.7 million, or $(0.02) per diluted share, compared to a net loss of $3.2 million, or $(0.02) per diluted share, in the third quarter of 2024. SSi Mantra surgical robotic system installations totaled 27, up 350.0% from 6 installations in the third quarter of 2024 and up 17.4% from 23 installations in the second quarter of 2025. First Nine Months 2025 Overview Revenue increased 123.0% to $28.0 million from $12.5 million in the first nine months of 2024. Gross margin expanded to 47.1% from 35.8% in the first nine months of 2024. Gross profit rose 193.7% to $13.2 million from $4.5 million in the first nine months of 2024. Net loss of $9.7 million, or $(0.05) per diluted share, compared to net loss of $17.2 million, or $(0.10) per diluted share, in the first nine months of 2024. SSi Mantra surgical robotic system installations totaled 63, up 152.0% from 25 installations in the first nine months of 2024. As of September 30, 2025 Long-term debt of $0. Cash and cash equivalents totaled $5.7 million, excluding restricted cash. SSi Mantra cumulative installed base totaled 127 in seven countries and cumulative surgeries reached 6,057, including 56 telesurgeries and 319 cardiac procedures. CEO Commentary Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We delivered strong revenue growth in the third quarter of 2025, driven by higher unit sales of our advanced, cost-effective SSi Mantra...

Explore SS Innovations International's Fair Values from the Community and select yours Revenue: US$10.0m (up 122% from 2Q 2024). Net loss: US$256.7k (loss narrowed by 94% from 2Q 2024). US$0.001 loss per share (improved from US$0.024 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period SS Innovations International shares are up 9.2% from a week ago. Before you take the next step you should know about the 3 warning signs for SS Innovations International that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

SS Innovations International (SSII) shares were up 10% in recent Thursday trading after the company

Record Quarterly Revenue of $10.0 Million Driven by Higher SSi Mantra 3 Unit Sales Gross Profit More than Tripled, Driven by Gross Margin Expansion and Revenue Growth FORT LAUDERDALE, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and six months ended June 30, 2025. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, with the Securities and Exchange Commission on August 6, 2025. Second Quarter 2025 Overview Revenue increased 121.8% to $10.0 million from $4.5 million in the second quarter of 2024. Gross margin expanded to 59.1% from 31.9% in the second quarter of 2024. Gross profit rose 311.4% to $5.9 million from $1.4 million in the second quarter of 2024. Net loss of $0.3 million, or $(0.00) per diluted share, compared to a net loss of $4.1 million, or $(0.02) per diluted share, in the second quarter of 2024. SSi Mantra surgical robotic system installations totaled 23, up 130% from 10 installations in the second quarter of 2024 and up 53% from 15 installations in the first quarter of 2025. First Half 2025 Overview Revenue increased 85.6% to $15.1 million from $8.1 million in the first half of 2024. Gross margin expanded to 46.3% from 26.6% in the first half of 2024. Gross profit rose 223.3% to $7.0 million from $2.2 million in the first half of 2024. Net loss of $5.9 million, or $(0.03) per diluted share, compared to net loss of $14.0 million, or $(0.08) per diluted share, in the first half of 2024. SSi Mantra surgical robotic system installations totaled 38, up 100% from 19 installations in the first half of 2024. As of June 30, 2025 Long-term debt of $0. Cash and cash equivalents totaled $11.4 million, excluding restricted cash. SSi Mantra cumulative installed base totaled 105 in seven countries and cumulative surgeries reached 4,657. CEO Commentary Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We continue to execute on our strategic initiatives and delivered strong revenue growth in the second quarter of 2025, driven by higher unit sales of our advanced, cost-effective SSi Mantra 3...

Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2025. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, with the Securities and Exchange Commission on May 14, 2025. First Quarter 2025 Overview Revenue increased 40.8% to $5.1 million from $3.6 million in the first quarter of 2024. Gross margin expanded 121 basis points to 21.23% from 20.02% in the first quarter of 2024. Gross profit rose 49.3% to $1.1 million from $0.7 million in the first quarter of 2024. Net loss of $5.7 million, or $(0.03) per diluted share, compared to net loss of $9.8 million, or $(0.06) per diluted share, in the first quarter of 2024. SSi Mantra surgical robotic system installations totaled 15, up 66.7% from 9 installations in the first quarter of 2024. As of March 31, 2025 Long-term debt of $0. Cash and cash equivalents totaled $15.9 million, excluding restricted cash. SSi Mantra cumulative installed base totaled 78 and cumulative surgeries reached 3,568. Subsequent Events On April 25, 2025, the Company’s common stock uplisted to The Nasdaq Capital Market®. CEO Commentary Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “In the first quarter of 2025, we achieved record quarterly revenue of $5.1 million, up 40.8% from $3.6 million in the first quarter of 2024, driven by higher unit sales of our innovative, cutting-edge SSi Mantra 3 surgical robotic system to leading healthcare facilities in India and abroad. Our gross margin also improved during the quarter, primarily reflecting a reduction in raw material prices. With an expanding installed base and growing utilization of SSi Mantra 3 by medical professionals globally, SS Innovations is well positioned for continued robust organic growth during the remainder of the year.” Dr. Srivastava continued, “After quarter end, we uplisted to Nasdaq, an exciting milestone that symbolizes...

FORT LAUDERDALE, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today reiterated guidance for the first quarter of 2025. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Following our recent uplisting to Nasdaq, we remain very pleased with the growth trajectory of our business as we conclude the first quarter of 2025 and enter the second quarter. We believe that we are well-positioned to maintain this momentum and achieve new and impactful milestones throughout 2025.” The Company reiterated: 14 SSi Mantra surgical robotic systems were installed during the first quarter of 2025, bringing the cumulative installed base to 78 as of March 31, 2025. Revenue for the first quarter of 2025 is expected to be approximately $6.4 million with a gross margin of approximately 45%, based on preliminary unaudited results which are subject to change. The Company also provided the following updates: As of April 30, 2025, 80 SSi Mantra robotic surgical systems have been installed in 75 hospitals and more than 3800 surgeries have utilized the SSi Mantra, including over 200 robotic cardiac surgeries. SSi Mantra robotic surgical system orders totaled 9 in the first month of the second quarter, April 2025, up 200% from 3 orders in April 2024. The Company anticipates reporting first quarter 2025 financial results on or about May 15, 2025. About SS Innovations SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi Mantr...